Literature DB >> 9194099

Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep.

J S Rothel1, D B Boyle, G W Both, A D Pye, J G Waterkeyn, P R Wood, M W Lightowlers.   

Abstract

Sheep were immunized with a protective recombinant antigen (45W) from the cestode parasite Taenia ovis using three different vaccine delivery systems, either alone or in different combinations. The DNA encoding 45W was cloned into the expression plasmid pcDNA 3 and an ovine adenovirus to create nucleic acid and recombinant viral vector vaccines, respectively. Sheep received two vaccinations with various combinations of these two delivery systems and/or purified recombinant 45W protein in a conventional vaccine formulation containing Quil A as adjuvant (protein/Quil A vaccine). Sheep receiving two inoculations of either the nucleic acid or the recombinant adenovirus alone, demonstrated only low levels of 45W-specific antibody. However, immunization with either nucleic acid or recombinant adenovirus primed animals to mount an enhanced immune response after a subsequent vaccination with the protein/ Quil A vaccine. The most striking result was that sheep initially immunized with the nucleic acid vaccine and boosted with the recombinant adenovirus, mounted IgG1 responses > 65 fold higher than those of sheep receiving either vaccine alone. The level of antibody in these sheep was commensurate with that observed in animals vaccinated twice with the protein/Quil A adjuvanted vaccine. In both cases, host-protection from experimental challenge infection with T. ovis was obtained.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194099     DOI: 10.1046/j.1365-3024.1997.d01-200.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

1.  Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep.

Authors:  P J Chaplin; R De Rose; J S Boyle; P McWaters; J Kelly; J M Tennent; A M Lew; J P Scheerlinck
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

2.  First step in characterization of cis-acting sequences involved in fowl adenovirus 1 (CELO) packaging and its effect on the development of a helper-dependent vector strategy.

Authors:  Claire Barra; Patrick Langlois
Journal:  Virus Genes       Date:  2008-09-30       Impact factor: 2.332

3.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.

Authors:  M Sedegah; T R Jones; M Kaur; R Hedstrom; P Hobart; J A Tine; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 4.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 5.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

Review 6.  Promising Technologies in the Field of Helminth Vaccines.

Authors:  Dilhan J Perera; Momar Ndao
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 7.561

7.  Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.

Authors:  George M Warimwe; Gema Lorenzo; Elena Lopez-Gil; Arturo Reyes-Sandoval; Matthew G Cottingham; Alexandra J Spencer; Katharine A Collins; Matthew D J Dicks; Anita Milicic; Amar Lall; Julie Furze; Alison V Turner; Adrian V S Hill; Alejandro Brun; Sarah C Gilbert
Journal:  Virol J       Date:  2013-12-05       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.